Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 11, 2011, Pages 1304-1310

  Dauden E ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

APPLICATION SITE BLEEDING; APPLICATION SITE BURNING; APPLICATION SITE DESQUAMATION; APPLICATION SITE DISCHARGE; APPLICATION SITE DISCOLORATION; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE PIGMENTATION CHANGE; APPLICATION SITE ULCER; ARTICLE; BASAL CELL CARCINOMA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HISTOLOGY; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIMARY TUMOR; PRIORITY JOURNAL; SELF REPORT; SUPERFICIAL BASAL CELL CARCINOMA; TUMOR VOLUME;

AGED; AMINOQUINOLINES; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 80054042870     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.03977.x     Document Type: Article

References (22)

1. Raasch B, Management of superficial basal cell carcinoma: focus on imiquimod. Clin Cosme Investig Dermatol 2009; 2: 65-75.
2. Wong CSM, Strange RC, Lear JT,. Basal cell carcinoma. BMJ 2003; 327: 794-798. (Pubitemid 37211176)
3. Raasch BA, Buettner PG, Garbe C,. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol 2006; 155: 401-407. (Pubitemid 44050576)
4. Tran H, Moreno G, Shumack S,. Imiquimoid as dermatological therapy. Expert Opin Pharmacother 2004; 5: 427-438.
5. Oldfield V, Keating GM, Perry CM,. Imiquimod: in superficial basal cell carcinoma. Am J Clin Dermatol 2005; 6: 195-200. (Pubitemid 40994262)
6. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML,. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-1007.
7. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-813. (Pubitemid 32391169)
8. Geisse JK, Rich P, Pandaya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-398.
9. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M,. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722-733. (Pubitemid 38580549)
10. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152: 939-947. (Pubitemid 40704934)
11. Bath-Hextall F, Bong J, Perkins W, Williams H,. Interventions for basal cell carcinoma of the skin: systematic review. BMJ 2004; 329: 705.
12. Bath-Hextall FJ, Perkins W, Bong J, Williams HC,. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007; 24: CD003412.
13. Ezughah FI, Dawe RS, Ibbotson SH, Fleming CJ,. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. J Dermatolog Treat 2008; 19: 111-117. (Pubitemid 351891551)
14. Quirk C, Gebauer K, Owens M, Stampone P,. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol 2006; 47: 258-265. (Pubitemid 44536221)
15. Ruiz-Villaverde R, Sánchez-Cano D, Burkhardt-Pérez P,. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series. J Eur Acad Dermatol Venereol 2009; 23: 828-831.
16. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008; 18: 677-682.
17. Sapijaszko MJ,. Imiquimod 5% cream (Aldara) in the treatment of basal cell carcinoma. Skin Therapy Lett 2005; 10: 2-5.
18. Novak N, Yu CF, Bieber T, Allam JP,. Toll-like receptor 7 agonists and skin. Drug News Perspect 2008; 21: 158-165. (Pubitemid 351809139)
19. Gaspari A, Tyring SK, Rosen T,. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 2009; 8: 467-474.
20. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005; 15: 374-381. (Pubitemid 41337416)
21. Vilata JJ, Badia X,. Effectiveness, satisfaction and compliance with imiquimod in the treatment of external anogenital warts. Int J STD AIDS 2003; 14: 11-17. (Pubitemid 36126984)
22. Hoyme UB, Hagedorn M, Schindler AE, et al. Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment. Infect Dis Obstet Gynecol 2002; 10: 79-88.